Latest Breaking News On - Tb partnership global drug facility - Page 1 : comparemela.com

Author summary Why was this study done? Drug resistance poses a major barrier to the effective treatment of tuberculosis, especially in Moldova and other post-Soviet states which have the highest levels of resistance in the world. Individuals with tuberculosis resistant to the key drug rifampicin face a worse prognosis, a longer and more expensive course of treatment, and more side effects than individuals with rifampicin-susceptible tuberculosis. Until recently, the standard of care for rifampicin-resistant tuberculosis (RR-TB) involved many drugs in combination, often given for 18 months or longer. The newer, 6-month “BPaLM” regimen is comprised of 4 drugs (bedaquiline, pretomanid, linezolid, and moxifloxacin) to which resistance levels are currently low, and while it was shown to be just as effective as the standard of care when health outcomes were measured at 72 weeks from treatment initiation, its effect on lifetime health outcomes, costs, and the acquisition of dru

United statesUnited kingdomSouth africaJennifer thorleyNational institute of allergyDecision science methods group at erasmus universityHarvard universityTb partnership global drug facilityHealth decision sciencePhd program in healthCreative commons attribution licenseNational instituteInfectious diseasesGlobal drug facilityConsumer price indexMoldovan leu